A study testing whether a new weekly shot, tirzepatide, can help people calm gut inflammation.
Recruiting now. Registry record last updated June 5, 2026.
- Who can join
- Adults 18 to 80, have Crohn's disease, BMI 25+.
- What you take
- tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3.3 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Crohn Disease (CD).
Full scientific study title: Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease.
Who can join
Adults 18 to 80, have Crohn's disease, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Subjects 18 to 80 years of age, inclusive, at the time of consent
- Confirmed diagnosis of Crohn's disease based on documented findings on endoscopy and histopathology
- Active ileal or ileocolonic inflammation on colonoscopy defined as
- Failure to respond to (primary or secondary non-response) at least 2 advanced class drugs, without evidence of immunogenicity (anti-TNFa only). Must have been at least 6 months optimized on most recent therapy without corticosteroids.
- Anti-TNF: Infliximab, Adalimumab, Certolizumab, Golimumab
Key exclusion criteria
- Age \< 18 or \> 80 years
- Pregnant or Breastfeeding female
- Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, diverticular disease-associated colitis, toxic megacolon, active infectious colitis or positive test for Clostridioides Difficile toxin at screening
- BMI \< 25
- Current or previous diagnosis of anorexia nervosa
Where this trial is enrolling
This trial has 3 sites across 3 states. Contact a site coordinator directly to start screening.
California1 site
- Cedars-Sinai Medical CenterBeverly Hills, California
Missouri1 site
- Washington University School of MedicineSt Louis, Missouri
New York1 site
- Icahn School of Medicine at Mount SinaiNew York, New York
Timeline
Started enrolling: May 13, 2025. Expected completion: August 2028. Last updated on ClinicalTrials.gov: June 5, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
